FPCP
RARE icon

Fort Point Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Fort Point Capital Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-8,000
Closed -$391K – 154
2016
Q2 		$391K Buy
+8,000
New +$518K 0.19% 77

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fort Point Capital Partners's RARE Position: Q3 2016 in Review

Fort Point Capital Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2016, closing a stake of 8,000 shares — an estimated $391K sold.

Fort Point Capital Partners first reported a position in RARE in Q2 2016 and held it in 1 quarter. The position peaked at $391K in Q2 2016. 172 funds tracked by Wall St. Rank hold RARE as of Q3 2016.

  • Fort Point Capital Partners reported no remaining Ultragenyx Pharmaceutical position as of Q3 2016 after selling out during the quarter.
  • Fort Point Capital Partners sold 8,000 Ultragenyx Pharmaceutical shares in Q3 2016, an estimated $391K.
  • Fort Point Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and held it in 1 quarter.
  • Fort Point Capital Partners's Ultragenyx Pharmaceutical position peaked at $391K in Q2 2016.
  • 172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2016.

Based on Fort Point Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.